These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 23739007)

  • 21. Treatment of Parkinson's disease--where do we go from here?
    Suchowersky O
    Nat Clin Pract Neurol; 2006 Sep; 2(9):461. PubMed ID: 16932605
    [No Abstract]   [Full Text] [Related]  

  • 22. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 25. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Parkinson disease. Directed use of modern therapy].
    Möller JC; Wächter T; Oertel WH
    MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is levodopa toxic?
    Müller T; Hefter H; Hueber R; Jost WH; Leenders KL; Odin P; Schwarz J
    J Neurol; 2004 Sep; 251 Suppl 6():VI/44-6. PubMed ID: 15675725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consideration about "Polyneuropathy in levodopa-treated Parkinson's patients".
    Coraci D; Santilli V; Giovannini S; Imbimbo I; Padua L
    J Neurol Sci; 2017 Apr; 375():1-2. PubMed ID: 28320110
    [No Abstract]   [Full Text] [Related]  

  • 29. When to Start Levodopa Therapy for Parkinson's Disease.
    Bressman S; Saunders-Pullman R
    N Engl J Med; 2019 Jan; 380(4):389-390. PubMed ID: 30673551
    [No Abstract]   [Full Text] [Related]  

  • 30. Abnormal upper gastrointestinal structures underlying levodopa malabsorption.
    Miyaue N; Yabe H; Nagai M; Nomoto M
    J Neurol Sci; 2020 Jul; 414():116855. PubMed ID: 32339970
    [No Abstract]   [Full Text] [Related]  

  • 31. Thrombocytopenia associated with levodopa treatment.
    Lee KE; Kang HS; Yu HJ; Roh SY
    J Mov Disord; 2013 May; 6(1):21-2. PubMed ID: 24868421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dietary antioxidants and Parkinson's disease.
    Ascherio A; Schwarzschild MA
    Mov Disord; 2017 Nov; 32(11):1501-1503. PubMed ID: 28976040
    [No Abstract]   [Full Text] [Related]  

  • 33. The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease.
    Błaszczyk JW
    Front Aging Neurosci; 2018; 10():301. PubMed ID: 30344487
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined Dopamine and Grape Seed Extract-Loaded Solid Lipid Nanoparticles: Nasal Mucosa Permeation, and Uptake by Olfactory Ensheathing Cells and Neuronal SH-SY5Y Cells.
    Trapani A; Castellani S; Guerra L; De Giglio E; Fracchiolla G; Corbo F; Cioffi N; Passantino G; Poeta ML; Montemurro P; Mallamaci R; Cardone RA; Conese M
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson's Disease, Necessary Again?
    Müller T
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Jing XZ; Yuan XZ; Luo X; Zhang SY; Wang XP
    Curr Neuropharmacol; 2023; 21(8):1806-1826. PubMed ID: 35193486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?
    Müller T
    Biologics; 2021; 15():307-316. PubMed ID: 34349499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.
    Müller T; Mueller BK; Riederer P
    Cells; 2021 Apr; 10(4):. PubMed ID: 33921342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.
    Müller T
    J Exp Pharmacol; 2021; 13():397-408. PubMed ID: 33824605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nutrition and Lifestyle Interventions for Managing Parkinson's Disease: A Narrative Review.
    Lister T
    J Mov Disord; 2020 May; 13(2):97-104. PubMed ID: 32498495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.